Urologicals

DrugDrug NameDrug Indication
DB00209TrospiumFor the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.
DB00346AlfuzosinFor the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia.
DB00496DarifenacinFor the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
DB00551Acetohydroxamic acidUsed, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.
DB00686Pentosan PolysulfateFor the relief of bladder pain or discomfort associated with interstitial cystitis.
DB00706TamsulosinTamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.[Label] Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.[A178339,L6259]
DB00770AlprostadilFor palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
DB00820TadalafilUsed for the treatment of erectile dysfunction.
DB00862VardenafilUsed for the treatment of erectile dysfunction
DB01036TolterodineFor the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
DB01062OxybutyninFor the treatment of overactive bladder.
DB01126DutasterideIndicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for BPH-related surgery alone or in combination with [tamsulosin].[label]
DB01148FlavoxateFor symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
DB01162TerazosinTerazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension[FDA Label].
DB01164Calcium ChlorideFor the treatment of hypocalcemia in those conditions requiring a prompt increase in blood plasma calcium levels, for the treatment of magnesium intoxication due to overdosage of magnesium sulfate, and used to combat the deleterious effects of hyperkalemia as measured by electrocardiographic (ECG), pending correction of the increased potassium level in the extracellular fluid.
DB01216FinasterideIndicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Indicated for the treatment of male pattern hair loss (androgenetic alopecia, hereditary alopecia, or common male baldness) in male patients.
DB01392YohimbineIndicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins.
DB01438PhenazopyridineFor the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.
DB01591SolifenacinFor the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
DB04884DapoxetineFor the treatment of premature ejaculation.
DB06207SilodosinTreatment for symptomatic relief of benign prostatic hyperplasia
DB06237AvanafilTreatment of erectile dysfunction in males.
DB06267UdenafilInvestigated for use/treatment in erectile dysfunction and hypertension.
DB06702FesoterodineFor the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
DB08893MirabegronMirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
DB09104Magnesium hydroxideMagnesium hydroxide can be used as an antacid or a laxative depending on the administered dose. As an antacid, it is used for the temporary relief of heartburn, upset stomach, sour stomach or acid indigestion. As a laxative, it is used for the relief of occasional constipation by promoting bowel movements for 30 minutes and up to 6 hours.
DB09205MoxisylyteBy the WHO, moxisylyte is indicated for the symptomatic management of sequelae of cerebral infarction or hemorrhage.[T91] The cerebral infarction is characterized by the blockage of the artery either by the formation of a thrombus or an embolus.[A31644] On the other hand, the FDA classified moxisylyte for the reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma.[L1172] Closed-angle glaucoma is caused by the contact between the iris and the trabecular meshwork. This contact will damage the aqueous outflow by the meshwork thus, increasing eye pressure and producing the symptoms of glaucoma.[A31645] Mydriasis is referred to the dilatation of the pupils and this standard body function is known to be a trigger factor for the development of acute closed-angle glaucoma.This risk is explained by the generation of a pupillary block, which is the contact between the pupillary margins and the lens, thus preventing flow from the aqueous humor to the anterior chamber and followed by an increased pressure gradient.[L1173] Moxisylyte is also approved in France as the first drug for the treatment of impotence.[A31647]
DB11071Phenyl salicylatePain and fever [L2468].
DB12278PropiverineIndicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB) [L2315]. Propiverine may also be used in patients with neurogenic bladder as a result of spinal cord injury [A32581].
DB13272MeladrazineNot Available
DB13376SuccinimideNot Available
DB13505EmeproniumNot Available
DB13725TerodilineNot Available
DB00714ApomorphineFor the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) associated with advanced Parkinson's disease.
DB01093Dimethyl sulfoxideFor the symptomatic relief of patients with interstitial cystitis.
DB01113PapaverineFor the treatment of impotence and vasospasms.
DB06767Ammonium chloride1. Expectorant in cough syrups. 2. The ammonium ion (NH4+) in the body plays an important role in the maintenance of acid-base balance. The kidney uses ammonium (NH4+) in place of sodium (Na+) to combine with fixed anions in maintaining acid-base balance, especially as a homeostatic compensatory mechanism in metabolic acidosis. The therapeutic effects of Ammonium Chloride depend upon the ability of the kidney to utilize ammonia in the excretion of an excess of fixed anions and the conversion of ammonia to urea by the liver, thereby liberating hydrogen (H+) and chloride (Cl–) ions into the extracellular fluid. Ammonium Chloride Injection, USP, after dilution in isotonic sodium chloride injection, may be indicated in the treatment of patients with: (1) hypochloremic states and (2) metabolic alkalosis.
DB13633MepartricinNot Available
DB06823TioproninTiopronin is indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria consisting of a urinary cystine concentration greater than 500 mg/day, and who have failed treatment with non-pharmacological measures of increased fluid intake, decreased sodium and protein intake, and urine alkalinization.
DB00203SildenafilSildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications: (1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and (2) treatment of pulmonary hypertension, where: a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850]; b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].
DrugDrug NameTargetType
DB00209TrospiumMuscarinic acetylcholine receptor M1target
DB00209TrospiumCytochrome P450 2D6enzyme
DB00346AlfuzosinAlpha-1A adrenergic receptortarget
DB00346AlfuzosinAlpha-1B adrenergic receptortarget
DB00346AlfuzosinAlpha-1D adrenergic receptortarget
DB00346AlfuzosinCytochrome P450 3A4enzyme
DB00346AlfuzosinPotassium voltage-gated channel subfamily H member 2target
DB00496DarifenacinMuscarinic acetylcholine receptor M3target
DB00496DarifenacinCytochrome P450 3A4enzyme
DB00496DarifenacinCytochrome P450 2D6enzyme
DB00496DarifenacinMuscarinic acetylcholine receptor M1target
DB00496DarifenacinMuscarinic acetylcholine receptor M2target
DB00496DarifenacinMuscarinic acetylcholine receptor M4target
DB00496DarifenacinMuscarinic acetylcholine receptor M5target
DB00551Acetohydroxamic acidUrease subunit alphatarget
DB00551Acetohydroxamic acidMacrophage metalloelastasetarget
DB00686Pentosan PolysulfateFibroblast growth factor 1target
DB00686Pentosan PolysulfateFibroblast growth factor 4target
DB00686Pentosan PolysulfateFibroblast growth factor 2target
DB00706TamsulosinAlpha-1A adrenergic receptortarget
DB00706TamsulosinAlpha-1D adrenergic receptortarget
DB00706TamsulosinAlpha-1B adrenergic receptortarget
DB00706TamsulosinAlpha-1-acid glycoprotein 1carrier
DB00706TamsulosinCytochrome P450 2D6enzyme
DB00706TamsulosinCytochrome P450 3A4enzyme
DB00770AlprostadilProstaglandin E2 receptor EP2 subtypetarget
DB00770AlprostadilProstaglandin E2 receptor EP1 subtypetarget
DB00770AlprostadilMultidrug resistance-associated protein 5transporter
DB00770AlprostadilSolute carrier organic anion transporter family member 2B1transporter
DB00770AlprostadilSolute carrier organic anion transporter family member 3A1transporter
DB00770AlprostadilMultidrug resistance-associated protein 4transporter
DB00770AlprostadilSolute carrier organic anion transporter family member 2A1transporter
DB00770AlprostadilProstaglandin D2 receptor 2target
DB00770AlprostadilSolute carrier family 22 member 6transporter
DB00820TadalafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00820TadalafilCytochrome P450 3A4enzyme
DB00820TadalafilDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11Atarget
DB00820TadalafilCytochrome P450 3A5enzyme
DB00862VardenafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00862VardenafilCytochrome P450 3A4enzyme
DB00862VardenafilRetinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00862VardenafilRetinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00862VardenafilCytochrome P450 3A5enzyme
DB00862VardenafilMultidrug resistance protein 1transporter
DB01036TolterodineMuscarinic acetylcholine receptor M1target
DB01036TolterodineMuscarinic acetylcholine receptor M2target
DB01036TolterodineMuscarinic acetylcholine receptor M3target
DB01036TolterodineCytochrome P450 2D6enzyme
DB01036TolterodineCytochrome P450 3A4enzyme
DB01036TolterodineCytochrome P450 2C9enzyme
DB01036TolterodineCytochrome P450 2C19enzyme
DB01036TolterodineMuscarinic acetylcholine receptor M4target
DB01036TolterodineMuscarinic acetylcholine receptor M5target
DB01062OxybutyninMuscarinic acetylcholine receptor M1target
DB01062OxybutyninMuscarinic acetylcholine receptor M2target
DB01062OxybutyninMuscarinic acetylcholine receptor M3target
DB01062OxybutyninCytochrome P450 3A4enzyme
DB01062OxybutyninCytochrome P450 2C8enzyme
DB01062OxybutyninCytochrome P450 2D6enzyme
DB01062OxybutyninCytochrome P450 3A5enzyme
DB01126Dutasteride3-oxo-5-alpha-steroid 4-dehydrogenase 1target
DB01126Dutasteride3-oxo-5-alpha-steroid 4-dehydrogenase 2target
DB01126DutasterideCytochrome P450 3A4enzyme
DB01126DutasterideSodium-dependent dopamine transportertransporter
DB01126DutasterideSynaptic vesicular amine transportertransporter
DB01126DutasterideSerum albumincarrier
DB01126DutasterideAlpha-1-acid glycoprotein 1carrier
DB01126DutasterideCytochrome P450 3A5enzyme
DB01148FlavoxateMuscarinic acetylcholine receptor M1target
DB01148FlavoxateMuscarinic acetylcholine receptor M2target
DB01162TerazosinAlpha-1A adrenergic receptortarget
DB01162TerazosinAlpha-1B adrenergic receptortarget
DB01162TerazosinAlpha-1D adrenergic receptortarget
DB01162TerazosinPotassium voltage-gated channel subfamily H member 2target
DB01162TerazosinPotassium voltage-gated channel subfamily H member 6target
DB01162TerazosinPotassium voltage-gated channel subfamily H member 7target
DB01162TerazosinMultidrug resistance protein 1transporter
DB01162TerazosinTransforming growth factor beta-1target
DB01164Calcium ChlorideProtein S100-A13target
DB01216Finasteride3-oxo-5-alpha-steroid 4-dehydrogenase 1target
DB01216FinasterideCytochrome P450 3A4enzyme
DB01216Finasteride3-oxo-5-alpha-steroid 4-dehydrogenase 2target
DB01216Finasteride3-oxo-5-beta-steroid 4-dehydrogenasetarget
DB01216FinasterideCytochrome P450 3A5enzyme
DB01216FinasterideCytochrome P450 3A7enzyme
DB01216FinasterideSolute carrier family 12 member 5transporter
DB01392YohimbineAlpha-2A adrenergic receptortarget
DB01392YohimbineAlpha-2B adrenergic receptortarget
DB01392YohimbineAlpha-2C adrenergic receptortarget
DB01392Yohimbine5-hydroxytryptamine receptor 1Atarget
DB01392Yohimbine5-hydroxytryptamine receptor 1Btarget
DB01392Yohimbine5-hydroxytryptamine receptor 1Dtarget
DB01392YohimbineD(2) dopamine receptortarget
DB01392YohimbineD(3) dopamine receptortarget
DB01392Yohimbine5-hydroxytryptamine receptor 2Atarget
DB01392Yohimbine5-hydroxytryptamine receptor 2Ctarget
DB01392YohimbineCytochrome P450 2D6enzyme
DB01392YohimbineCytochrome P450 3A4enzyme
DB01392YohimbineATP-sensitive potassium channeltarget
DB01392Yohimbine5-hydroxytryptamine receptor 2Btarget
DB01438PhenazopyridineSodium channel protein type 1 subunit alphatarget
DB01591SolifenacinMuscarinic acetylcholine receptor M3target
DB01591SolifenacinMuscarinic acetylcholine receptor M1target
DB01591SolifenacinCytochrome P450 3A4enzyme
DB01591SolifenacinMuscarinic acetylcholine receptor M2target
DB01591SolifenacinMuscarinic acetylcholine receptor M4target
DB01591SolifenacinMuscarinic acetylcholine receptor M5target
DB04884Dapoxetine5-hydroxytryptamine receptor 1Atarget
DB04884Dapoxetine5-hydroxytryptamine receptor 1Btarget
DB04884Dapoxetine5-hydroxytryptamine receptor 2Ctarget
DB04884DapoxetineCytochrome P450 3A4enzyme
DB04884DapoxetineCytochrome P450 2D6enzyme
DB06207SilodosinAlpha-1D adrenergic receptortarget
DB06207SilodosinCytochrome P450 3A4enzyme
DB06207SilodosinMultidrug resistance protein 1transporter
DB06207SilodosinMultidrug resistance protein 3transporter
DB06207SilodosinAlpha-1A adrenergic receptortarget
DB06207SilodosinAlpha-1B adrenergic receptortarget
DB06207SilodosinUDP-glucuronosyltransferase 2B7enzyme
DB06237AvanafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB06237AvanafilCytochrome P450 3A4enzyme
DB06267UdenafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB06267UdenafilCytochrome P450 3A4enzyme
DB06267UdenafilCytochrome P450 3A5enzyme
DB06702FesoterodineMuscarinic acetylcholine receptor M1target
DB06702FesoterodineMuscarinic acetylcholine receptor M3target
DB06702FesoterodineCytochrome P450 3A4enzyme
DB06702FesoterodineMuscarinic acetylcholine receptor M2target
DB06702FesoterodineMuscarinic acetylcholine receptor M4target
DB06702FesoterodineMuscarinic acetylcholine receptor M5target
DB06702FesoterodineCytochrome P450 2D6enzyme
DB06702FesoterodineMultidrug resistance protein 1transporter
DB08893MirabegronCytochrome P450 3A4enzyme
DB08893MirabegronCytochrome P450 2D6enzyme
DB08893MirabegronMultidrug resistance protein 1transporter
DB08893MirabegronSolute carrier organic anion transporter family member 1A2transporter
DB08893MirabegronSerum albumincarrier
DB08893MirabegronAlpha-1-acid glycoprotein 1carrier
DB08893MirabegronCholinesteraseenzyme
DB08893MirabegronBeta-3 adrenergic receptortarget
DB09205MoxisylyteCholinesteraseenzyme
DB09205MoxisylyteCytochrome p450 3A subfamilyenzyme
DB09205MoxisylyteAlpha adrenergic receptortarget
DB11071Phenyl salicylateProstaglandin G/H synthase 1target
DB11071Phenyl salicylateProstaglandin G/H synthase 2target
DB12278PropiverineMuscarinic acetylcholine receptor M1target
DB12278PropiverineMuscarinic acetylcholine receptor M2target
DB12278PropiverineMuscarinic acetylcholine receptor M3target
DB12278PropiverineMuscarinic acetylcholine receptor M4target
DB12278PropiverineMuscarinic acetylcholine receptor M5target
DB12278PropiverineVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB12278PropiverineAlpha-1A adrenergic receptortarget
DB12278PropiverineCytochrome P450 3A4enzyme
DB12278PropiverineDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB12278PropiverineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB12278PropiverineCYP2B proteinenzyme
DB13725TerodilineCytochrome P450 3A4enzyme
DB00714ApomorphineD(2) dopamine receptortarget
DB00714ApomorphineD(1A) dopamine receptortarget
DB00714ApomorphineD(4) dopamine receptortarget
DB00714ApomorphineD(3) dopamine receptortarget
DB00714ApomorphineD(1B) dopamine receptortarget
DB00714ApomorphineNeuron-specific vesicular protein calcyontarget
DB00714ApomorphineAlpha-2C adrenergic receptortarget
DB00714ApomorphineAlpha-2B adrenergic receptortarget
DB00714Apomorphine5-hydroxytryptamine receptor 2Ctarget
DB00714Apomorphine5-hydroxytryptamine receptor 1Atarget
DB00714Apomorphine5-hydroxytryptamine receptor 2Atarget
DB00714Apomorphine5-hydroxytryptamine receptor 2Btarget
DB00714ApomorphineAlpha-2A adrenergic receptortarget
DB00714Apomorphine5-hydroxytryptamine receptor 1Dtarget
DB00714Apomorphine5-hydroxytryptamine receptor 1Btarget
DB01093Dimethyl sulfoxideTransthyretincarrier
DB01093Dimethyl sulfoxideCytochrome P450 2C19enzyme
DB01093Dimethyl sulfoxideCytochrome P450 2D6enzyme
DB01093Dimethyl sulfoxideCytochrome P450 3A4enzyme
DB01113PapaverinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB01113PapaverinecAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10Atarget
DB13633MepartricinCytochrome P450 3A4enzyme
DB06823TioproninMyeloperoxidaseenzyme
DB00203SildenafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00203SildenafilCytochrome P450 2C9enzyme
DB00203SildenafilRetinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00203SildenafilRetinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00203SildenafilCytochrome P450 3A4enzyme
DB00203SildenafilCytochrome P450 3A5enzyme
DB00203SildenafilCytochrome P450 3A7enzyme
DB00203SildenafilMultidrug resistance-associated protein 4transporter
DB00203SildenafilMultidrug resistance-associated protein 5transporter
DB00203SildenafilMultidrug resistance-associated protein 7transporter
DB00203SildenafilCytochrome P450 2C19enzyme
DB00203SildenafilCytochrome P450 2D6enzyme
DB00203SildenafilCytochrome P450 1A1enzyme
DB00203SildenafilCytochrome P450 2E1enzyme
DB00203SildenafilSolute carrier organic anion transporter family member 1B1transporter
DB00203SildenafilMultidrug resistance protein 1transporter